National Strategic Research Institute (NSRI) Fellow Paul Davis is leading a research team of technicians, graduate students and undergraduate students to develop an agent that can be administered either prior to or following viral exposure to prevent illnesses such as COVID-19. The project is one of seven funded through the NSRI independent research and development program, launched in 2021.
This particular anti-infective therapy is distinct because it has the potential to be self-administered as a nasal spray. So far, the team has reached three key milestones:
- Safety established in animal models
- Scale-up synthesis for testing in models
- Early anti-viral responses show promising results
Next, the team will conduct research to understand the safety and efficacy of the therapy in treating coronavirus infection.
If successful, the Department of Defense can benefit from this work by providing an effective and efficient anti-viral therapy to our Nation's warfighters.
Learn more about NSRI's 2021 IRAD projects at nsri.nebraska.edu/irad2021.
Details about our capabilities for medical countermeasures and response are available at nsri.nebraska.edu/medical.
About the National Strategic Research Institute
Through the National Strategic Research Institute at the University of Nebraska leading scientists deliver innovative national security research, technology, product and strategy development, training and exercises, and subject matter expertise to the Department of Defense and other federal agencies. One of only 14 DOD-designated University Affiliated Research Centers in the country, NSRI is sponsored by U.S. Strategic Command and works to ensure the United States’ safety and preparedness against increasingly sophisticated threats. Read about our mission.